|
Volumn 52, Issue 2, 2001, Pages 181-188
|
Interleukin-12 in the treatment of chronic hepatitis B and C
|
Author keywords
HBV DNA levels; HCV RNA levels; Interferon ; Interleukin 10; Interleukin 12
|
Indexed keywords
AMINOTRANSFERASE;
ANTIVIRUS AGENT;
BILIRUBIN;
GAMMA INTERFERON;
RECOMBINANT INTERLEUKIN 12;
VIRUS DNA;
VIRUS RNA;
ADULT;
AMINOTRANSFERASE BLOOD LEVEL;
ANTIVIRAL ACTIVITY;
ARTICLE;
BILIRUBIN BLOOD LEVEL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG TOLERABILITY;
FEMALE;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
LEUKOCYTE COUNT;
LYMPHOCYTE;
MALE;
MULTICENTER STUDY;
NEUTROPHIL;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
VIRUS CONCENTRATION;
VIRUS DETECTION;
VIRUS INFECTION;
ADOLESCENT;
ADULT;
FEMALE;
HEPATITIS B, CHRONIC;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON TYPE II;
INTERLEUKIN-10;
INTERLEUKIN-12;
MALE;
MIDDLE AGED;
RECOMBINANT PROTEINS;
HEPATITIS B VIRUS;
HEPATITIS C VIRUS;
|
EID: 0034769082
PISSN: 01663542
EISSN: None
Source Type: Journal
DOI: 10.1016/S0166-3542(01)00183-8 Document Type: Article |
Times cited : (34)
|
References (32)
|